Reports Q1 revenue $12.69M, consensus $10.87M. "Nurix had a strong start to 2023 with the recent announcement that Gilead has licensed the first of our five collaboration programs, a targeted protein degrader of IRAK4, triggering a $20M payment to Nurix and setting the stage for potential achievement of additional milestone payments," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "The advancement of our IRAK4 program marks the achievement of one of our key goals in 2023 and highlights the capability of our platform to create drug candidates for therapeutic areas outside oncology such as inflammatory disease. We look forward to the continued advancement of our exciting pipeline including our wholly owned and partnered programs."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NRIX:
- Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
- Nurix Therapeutics management to meet with Piper Sandler
- Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
- Nurix Therapeutics, Inc. (NRIX) Q1 Earnings Cheat Sheet
- Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news